Regitine, Rogitine 
Classifications: autonomic nervous system agent; alpha-adrenergic antagonist (blocking agent), sympatholytic
Prototype: Prazosin
Pregnancy Category: C


5 mg injection


Alpha-adrenergic blocking agent structurally related to tolazoline but with more potent blocking effects. Competitively blocks alpha-adrenergic receptors, but action is transient and incomplete. Prevents hypertension resulting from elevated levels of circulating epinephrine or norepinephrine.

Therapeutic Effects

Causes vasodilation and decreases general vascular resistance and pulmonary arterial pressure, primarily by direct action on vascular smooth muscle. Through stimulation of beta-adrenergic receptors, produces positive inotropic and chronotropic cardiac effects and increases cardiac output.


Diagnosis of pheochromocytoma and to prevent or control hypertensive episodes prior to or during pheochromocytomectomy.

Unlabeled Uses

Prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine.


MI (previous or present), coronary artery disease. Safety during pregnancy (category C) or lactation is not established.

Cautious Use

Gastritis, peptic ulcer.

Route & Dosage

To Prevent Hypertensive Episode during Surgery
Adult: IV/IM 2–5 mg as needed
Child: IV/IM 1 mg or 0.1 mg/kg (max: 5 mg/dose)

To Test for Pheochromocytoma
Adult: IV/IM 5 mg
Child: IV/IM 0.1 mg/kg

To Prevent Necrosis from Norepinephrine Infusions
Adult: IV 10 mg added to each liter of IV fluid containing norepinephrine

To Treat Catecholamine Extravasation
Adult/Child: Intradermal 5–10 mg diluted in 10 mL of normal saline injected into affected area within 12 h of extravasation
Neonate: Intradermal 2.5–5 mg diluted in 10 mL of normal saline injected into affected area within 12 h of extravasation (max: dose 0.1 mg/kg or 2.5 mg total)


Note: Place patient in supine position when receiving drug parenterally. Monitor BP and pulse q2min until stabilized.


PREPARE: Direct: Reconstitute as for IM. May be further diluted with up to 10 mL of sterile water. Use immediately.  

ADMINISTER: Direct: Give a single dose over 60 sec.  

Adverse Effects (1%)

Body as a Whole: Weakness, dizziness, flushing, orthostatic hypotension. GI: Abdominal pain, nausea, vomiting, diarrhea, exacerbation of peptic ulcer. CV: Acute and prolonged hypotension, tachycardia, anginal pain, cardiac arrhythmias, MI, cerebrovascular spasm, shock-like state. Special Senses: Nasal stuffiness, conjunctival infection.


Drug: may antagonize BP raising effects of epinephrine, ephedrine.


Peak: 2 min IV; 15–20 min IM. Duration: 10–15 min IV; 3–4 h IM. Elimination: Excreted in urine. Half-Life: 19 min.

Nursing Implications

Assessment & Drug Effects

Patient & Family Education

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug